1-5 of 5
William A. Wegener
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan

Available to Purchase
Jhanelle E. Gray, Rebecca S. Heist, Alexander N. Starodub, D. Ross Camidge, Ebenezer A. Kio, Gregory A. Masters, W. Thomas Purcell, Michael J. Guarino, Jamal Misleh, Charles J. Schneider, Bryan J. Schneider, Allyson Ocean, Tirrell Johnson, Leena Gandhi, Kevin Kalinsky, Ronald Scheff, Wells A. Messersmith, Serengulam V. Govindan, Pius P. Maliakal, Boyd Mudenda, William A. Wegener, Robert M. Sharkey, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5711–5719.
https://doi.org/10.1158/1078-0432.CCR-17-0933
Published: 01 October 2017
View articletitled, Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan
Open the PDF for Therapy of Small Cell Lung Cancer (SCLC) with a Topoisomerase-I–inhibiting Antibody–Drug Conjugate (ADC) Targeting Trop-2, Sacituzumab Govitecan in another window
Includes: Supplementary data
Journal Articles

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

Available to Purchase
Alexander N. Starodub, Allyson J. Ocean, Manish A. Shah, Michael J. Guarino, Vincent J. Picozzi, Jr, Linda T. Vahdat, Sajeve S. Thomas, Serengulam V. Govindan, Pius P. Maliakal, William A. Wegener, Steven A. Hamburger, Robert M. Sharkey, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (17): 3870–3878.
https://doi.org/10.1158/1078-0432.CCR-14-3321
Published: 31 August 2015
View articletitled, First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors
Open the PDF for First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial

Available to Purchase
Seza A. Gulec, Steven J. Cohen, Kenneth L. Pennington, Lionel S. Zuckier, Ralph J. Hauke, Heather Horne, William A. Wegener, Nick Teoh, David V. Gold, Robert M. Sharkey, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (12): 4091–4100.
https://doi.org/10.1158/1078-0432.CCR-10-2579
Published: 15 June 2011
View articletitled, Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial
Open the PDF for Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial in another window
Journal Articles

Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab

Available to Purchase
Ola Lindén, Cecilia Hindorf, Eva Cavallin-Ståhl, William A. Wegener, David M. Goldenberg, Heather Horne, Tomas Ohlsson, Lars Stenberg, Sven-Erik Strand, Jan Tennvall
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (14): 5215–5222.
https://doi.org/10.1158/1078-0432.CCR-05-0172
Published: 20 July 2005
View articletitled, Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab
Open the PDF for Dose-Fractionated Radioimmunotherapy in Non-Hodgkin's Lymphoma Using DOTA-Conjugated, 90Y-Radiolabeled, Humanized Anti-CD22 Monoclonal Antibody, Epratuzumab in another window
Journal Articles

Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma: Phase I/II Clinical Trial Results

Available to Purchase
John P. Leonard, Morton Coleman, Jamie C. Ketas, Amy Chadburn, Richard Furman, Michael W. Schuster, Eric J. Feldman, Michelle Ashe, Stephen J. Schuster, William A. Wegener, Hans J. Hansen, Heather Ziccardi, Michael Eschenberg, Urte Gayko, Scott Z. Fields, Alessandra Cesano, David M. Goldenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (16): 5327–5334.
https://doi.org/10.1158/1078-0432.CCR-04-0294
Published: 24 August 2004
View articletitled, Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma: Phase I/II Clinical Trial Results
Open the PDF for Epratuzumab, a Humanized Anti-CD22 Antibody, in Aggressive Non-Hodgkin’s Lymphoma: Phase I/II Clinical Trial Results in another window